FDA Approves First Drug to Treat Fatty Liver Disease
• FDA approves first ever drug, called Rezdiffra, to treat nonalcoholic steatohepatitis (NASH), a common liver disease • Rezdiffra activates thyroid hormone receptors to reduce fat buildup and inflammation in the liver • In trials, over 25% of patients taking Rezdiffra achieved NASH resolution without worsening fibrosis • The drug also helped lower LDL cholesterol and liver enzyme levels • Rezdiffra received accelerated FDA approval; further trials are needed to verify long-term clinical benefit